As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs could put it back on the right track. While profit margins may slip due to the price cuts, the company could ultimately benefit more from making its drugs more accessible to patients.

Until the end of March, Novo Nordisk will let people with prescriptions buy the first two doses of the drugs for $199 a month. Then the monthly cost will rise to $349.

The Danish drugmaker said it's cutting the price of Wegovy and Ozempic from $499 to $349 per month for some customers who buy the drugs directly.

Novo Nordisk said on Monday it has begun selling its popular weight-loss drug Wegovy for $349 a month to cash payers, months ahead of the timeline set out with the Trump administration.

On November 24, 2025, Novo Nordisk announced top-line results from its phase 3 evoke and evoke+ trials, revealing that oral semaglutide did not show superiority over placebo in slowing progression of early-stage symptomatic Alzheimer's disease,

The company that sells Ozempic and Wegovy, drugs known for promoting easy weight loss, is now selling the products at Costco.

Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its Ozempic shot, originally developed to treat diabetes, could help trim their waistlines.

The authority said the cases were complex because semaglutide has been linked in very rare situations to non-arteritic anterior ischemic optic neuropathy, a condition that can cause permanent vision loss.